SEREND-IP GMBH

Their core work

SEREND-IP GmbH is a small German private company based in Münster whose name strongly suggests a focus on intellectual property in the life sciences — likely translating or commercializing biomedical research findings. Their participation in two MSCA-RISE projects (a researcher-exchange scheme) indicates they serve as an industry node connecting academic scientists with commercial opportunities, rather than conducting primary research themselves. Both projects they joined — one in cancer glycobiology and one in the molecular biology of endometriosis — point to a specialisation in molecular medicine and women's health or oncology. Their very modest EC funding (EUR 18,000 total) is characteristic of MSCA-RISE industry participants who receive reimbursement for hosting or sending researchers on secondment, not for running lab work.

What they specialise in

How they've shifted over time

Both H2020 projects began within a single year of each other (2015 and 2016) and ran through 2019, so there is no meaningful early-versus-late shift to draw from the timeline. What is visible is a thematic arc within that window: from extracellular matrix biology and oncology (GLYCANC) toward intracellular molecular signalling in a chronic disease context (MOMENDO), suggesting a broadening from cancer-focused glycoscience into molecular reproductive medicine. No post-2019 H2020 activity is recorded, so whether the organisation continued this trajectory or pivoted cannot be determined from the available data.

Their two projects suggest an interest in molecular pathology across oncology and chronic disease, but with only two early-stage engagements and no post-2019 data, the direction of any future collaboration is unclear.

How they like to work

SEREND-IP has participated exclusively as a consortium partner, never as coordinator, across both H2020 projects — a pattern consistent with a specialist contributor rather than a project leader. Despite their small size, they have engaged with 18 distinct partners across 13 countries through MSCA-RISE networks, which tend to involve large multi-node consortia by design. This suggests they are comfortable operating in broad international settings but in a supporting or facilitating role, likely hosting or dispatching researchers rather than setting research agendas.

SEREND-IP has built connections with 18 consortium partners across 13 countries, an unusually broad reach for a two-project SME — a direct result of the MSCA-RISE scheme's multi-institution exchange structure. Their network is pan-European in character with no identifiable geographic concentration beyond their German base.

What sets them apart

SEREND-IP occupies a rare niche as a private German SME embedded in academic life-sciences consortia via the MSCA researcher-exchange programme — a role usually filled by universities. Their likely IP or technology-transfer function means they can serve as a bridge between academic discoveries in molecular medicine and commercial exploitation, which is a profile rarely found among project partners in the MSCA-RISE ecosystem. For a consortium builder, they offer an industry checkpoint for IP awareness without the overhead of a large industrial partner.

Highlights from their portfolio

• MOMENDO
  The larger of the two grants (EUR 13,500) and focused on endometriosis — a chronically underfunded disease area with growing commercial and clinical interest — making it the more strategically significant engagement.
• GLYCANC
  Addresses glycan-based therapeutic targets in cancer, an area with direct drug-development relevance that aligns well with an IP-focused commercial partner's potential licensing or spin-out activities.